Regarding the establishment of tumor-promoting inflammation, KRAS was shown to be capable of inducing cytokine secretion such as IL-6 and reduced secretion of IFNγ, TNF, and IL-2 by different stromal cell types, e.g., fibroblasts, myoblasts and epithelial cells. The gene discussed is IL2; the disease is neoplasm.